This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mouton, J. W.
Right arrow Articles by Vinks, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mouton, J. W.
Right arrow Articles by Vinks, A. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3449-3451, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01586-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo{triangledown}

Johan W. Mouton,1* Nieko Punt,2 and Alexander A. Vinks3

Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands,1 Medimatics, Maastricht, The Netherlands,2 Pediatric Pharmacology Research Unit, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio3

Received 20 December 2006/ Returned for modification 26 March 2007/ Accepted 11 June 2007

Growth-kill dynamics were characterized in vitro, and the parameter estimates were used to simulate bacterial growth and kill in vivo using both mouse and human pharmacokinetics. The parameter estimates obtained in vitro predicted a time above the MIC of between 35 and 38% for a static effect in mice after 24 h of treatment.

* Corresponding author. Mailing address: Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Ziekenhuis Nijmegen, Weg door Jonkerbos 100, 6532 sz Nijmegen, The Netherlands. Phone: 31-(0)24-3657514. Fax: 31-(0)24-3657516. E-mail: Mouton{at}cwz.nl

{triangledown} Published ahead of print on 18 June 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3449-3451, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01586-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Livermore, D. M., Tulkens, P. M. (2009). Temocillin revived. J Antimicrob Chemother 63: 243-245 [Abstract] [Full Text]  
  • De Jongh, R., Hens, R., Basma, V., Mouton, J. W., Tulkens, P. M., Carryn, S. (2008). Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 61: 382-388 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»